Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
1 report, 1 independent
Updated Wed 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.
- AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.